

# Ontario Public Drug Programs

Drug Submission Status  
Updated: March 13, 2015

## Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

| Manufacturer               | Product         | Reference Product | Generic Name | Strength | Dosage Form | DIN      |
|----------------------------|-----------------|-------------------|--------------|----------|-------------|----------|
| Natco Pharma (Canada) Inc. | Nat-Letrozole   | Femara            | letrozole    | 2.5mg    | FC tablet   | 02421585 |
| Natco Pharma (Canada) Inc. | Nat-Anastrozole | Arimidex          | anastrozole  | 1mg      | FC tablet   | 02417855 |
| Pharmascience Inc.         | Telmisartan     | Micardis          | telmisartan  | 40mg     | tablet      | 02432897 |
| Pharmascience Inc.         | Telmisartan     | Micardis          | telmisartan  | 80mg     | tablet      | 02432900 |
| Pharmascience Inc.         | Lansoprazole    | Prevacid          | lansoprazole | 30mg     | DR capsule  | 02433028 |